Skip to content

Loss of asymmetric spine synapses in dorsolateral prefrontal cortex of cognitively impaired phencyclidine-treated monkeys.

John D Elsworth, Tibor Hajszan, Csaba Leranth, Robert H Roth

The International Journal of Neuropsychopharmacology November 2011 DOI: 10.1017/s1461145711000939 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational animal study Peer reviewed
Population Monkeys treated with phencyclidine (PCP) and vehicle-treated controls
Intervention Phencyclidine (PCP)
Key findings Subchronic PCP treatment decreased the number of asymmetric spine synapses in the dorsolateral prefrontal cortex of monkeys, with a greater reduction in layer II/III than layer V compared with vehicle-treated controls. The authors propose this synapse loss may contribute to PCP-induced cognitive dysfunction and possibly to schizophrenia, and suggest it as a target for treatment development.

Abstract

Schizophrenia patients, long-term abusers of phencyclidine (PCP), and monkeys treated with PCP all exhibit enduring cognitive deficits. Evidence indicates that loss of prefrontal cortex spine synapses results in cognitive dysfunction, suggesting the presence of synaptic pathology in the monkey PCP model; however, there is no direct evidence of such changes. In this study we use the monkey PCP model of schizophrenia to investigate at the ultrastructural level whether remodelling of dorsolateral prefrontal cortex (DLPFC) asymmetric spine synapses occurs following PCP. Subchronic PCP treatment resulted in a decrease in the number of asymmetric spine synapses, which was greater in layer II/III than layer V of DLPFC, compared to vehicle-treated controls. This decrease may contribute to PCP-induced cognitive dysfunction in the non-human primate model and perhaps in schizophrenia. Thus, the synapse loss in the PCP model provides a novel target for the development of potential treatments of cognitive dysfunction in this model and in schizophrenia.

Citations in the library